A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Issue 38 (11th September 2015)

• Record Type: Journal Article
• Authors: Gupta, Sachin; Termini, James M.; Rivas, Yaelis; Otero, Miguel; Raffa, Francesca N.; Bhat, Vikas; Farooq, Amjad; Stone, Geoffrey W.
• Is Part Of: Vaccine. Volume 33:Issue 38(2015)
• Page Start: 4798
• Page End: 4806
• Publication Date: 2015-09-11
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.07.081
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">DNA vaccine technology fusing cancer antigens to CD40L soluble multi-trimers.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">Allows targeting of vaccine antigens to dendritic cells in situ.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">Activates and matures dendritic cells.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">Vaccine induces an anti-tumor immune response when combined with IL-12 and GM-CSF.</p> </list-item> </list> </p> </sec> </abstract>